GLP-1 hormone support: Helps promote satiety and natural appetite control, aligning with current gut hormone research trends
Key Takeaway The NICE 2026 update highlights a shift from purely glycaemic control to early cardiovascular and renal protection, supporting the earlier use of SGLT2 inhibitors and GLP-1based therapies in appropriate patients
Pan LY, Kuo YK, Chen TH, Sun CC
In contrast, researchers found that adolescents who had at least one exacerbation in the GLP-1 receptor agonist group had a comparable number of subsequent events over 12 months when compared with adolescents who had at least one exacerbation in the control group (mean, 1.83 vs
The most important thing is to stay consistent once youve made the change, and to make sure youre not taking doses too close together during the transition
On top of that, one of the five ways a medical weight loss specialist can help you involves weight management